Published in Ther Clin Risk Manag on March 26, 2009
The role of surfactant in respiratory distress syndrome. Open Respir Med J (2012) 0.90
Gestational exposure of mice to secondhand cigarette smoke causes bronchopulmonary dysplasia blocked by the nicotinic receptor antagonist mecamylamine. Environ Health Perspect (2013) 0.80
Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study. Yonsei Med J (2015) 0.77
Clinical effects of pulmonary surfactant in combination with nasal continuous positive airway pressure therapy on neonatal respiratory distress syndrome. Pak J Med Sci (2017) 0.75
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med (2001) 4.68
Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet (2000) 4.55
Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med (1993) 3.33
Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev (2001) 2.04
A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics (2005) 1.80
Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med (2000) 1.78
A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol (2004) 1.75
A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics (2005) 1.70
Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed (1995) 1.60
Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr (2003) 1.57
Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med (1994) 1.51
Platelet-activating factor in surfactant preparations. Lancet (1993) 1.48
Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr (2000) 1.43
Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev (2001) 1.22
Antenatal associations with lung maturation and infection. J Perinatol (2005) 1.11
Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatr Pulmonol (1999) 1.09
Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr (1997) 1.06
Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics (1997) 1.01
A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr (2005) 0.99
Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics (1991) 0.98
Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics (2005) 0.97
Animal-derived surfactants versus past and current synthetic surfactants: current status. Clin Perinatol (2007) 0.90
Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases. Acta Paediatr (2006) 0.88
A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics (1997) 0.85
Surfactant. Evolving issues. Clin Perinatol (1998) 0.85
New synthetic surfactants: the next generation? Biol Neonate (2005) 0.83
Surfactant for respiratory distress syndrome: are there important clinical differences among preparations? Curr Opin Pediatr (2007) 0.82
Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents? Paediatr Drugs (2002) 0.81
Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial. J Perinatol (2004) 0.80
A comparison of efficacy between two natural exogenous surfactant preparations in premature infants with respiratory distress syndrome. Klin Padiatr (2004) 0.80
Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc (1994) 0.80
Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev (2007) 0.79
Randomized clinical trial comparing two natural surfactant preparations to treat respiratory distress syndrome. J Matern Fetal Neonatal Med (2004) 0.79
A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr (1996) 0.79
A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network. Pediatrics (1996) 0.78
Comparative efficacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol (1998) 0.78
Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics (2007) 1.90
Randomized, controlled trial of slow versus rapid feeding volume advancement in preterm infants. Pediatrics (2004) 1.44
Risk factors predicting vasopressor use after patent ductus arteriosus ligation. Am J Perinatol (2003) 1.23
Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia. J Pediatr Surg (2004) 0.97
Regulation of human pulmonary surfactant protein gene expression by 1alpha,25-dihydroxyvitamin D3. Am J Physiol Lung Cell Mol Physiol (2005) 0.94
Longitudinal assessment of heart rate variability in very low birth weight infants during their NICU stay. Early Hum Dev (2006) 0.87
Surfactant replacement therapy on ECMO does not improve outcome in neonates with congenital diaphragmatic hernia. J Pediatr Surg (2004) 0.83
A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure. Pediatr Crit Care Med (2012) 0.80
A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa. J Pediatr Pharmacol Ther (2012) 0.80
Interaction of an artificial surfactant in human pulmonary epithelial cells. Pediatr Pulmonol (2005) 0.79
Surfactant trials. Pediatrics (2006) 0.78